title: [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
abstract: In order to evaluate the significance as a parameter for monitoring immunological status and for predicting therapeutic effect and prognosis, Su-PS skin test was performed in 68 cases of primary lung cancer treated with chemotherapy and administration of OK-432. In 16 of 68 cases, lymphocyte subsets of peripheral blood using Leu monoclonal antibodies were analyzed to investigate the immunological status. Su-PS skin test was performed at the time of before treatment, 1 week after administration of OK-432, 4 weeks after chemotherapy and intervals during treatment. The reactions to Su-PS skin test in these patients were divided into 3 groups according to the maximum size during the treatment as follows; less than 20 mm, 20 mm to 50 mm and over 50 mm. As compared with the reaction to Su-PS skin test and the survival, there was a significant difference between each group. The analysis of the lymphocyte subsets also indicated that immunological status tended to be activated more in strong responders to the Su-PS skin test than in weak responders. Therefore, Su-PS skin test is considered to be an useful immunological parameter of cancer patients under treatment.
authors.affiliation: Dept. of Surgery, Ohmuta Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Horiuchi
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: I
authors.initials: I
authors.lastname: Nakarai
authors.forename: A
authors.initials: A
authors.lastname: Shinoda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D011135:Polysaccharides, Bacterial; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D012882:Skin Tests; D013297:Streptococcus pyogenes / Q000276:immunology
chemical_list: D001688:Biological Products; D011135:Polysaccharides, Bacterial; C036112:streptococcal polysaccharide group A; D010844:Picibanil